(Q44163692)

17 June 2018

title

Dose-response trial of lactoferrin in patients with chronic hepatitis C. (English)

1 reference

17 June 2018

author name string

Shuichi Okada

1

1 reference

17 June 2018

Katsuaki Tanaka

2

1 reference

17 June 2018

Tosiya Sato

3

1 reference

17 June 2018

Hideki Ueno

4

1 reference

17 June 2018

Satoru Saito

5

1 reference

17 June 2018

Takuji Okusaka

6

1 reference

17 June 2018

Keiko Sato

7

1 reference

17 June 2018

Seiichiro Yamamoto

8

1 reference

17 June 2018

Tadao Kakizoe

9

1 reference

17 June 2018

publication date

1 September 2002

1 reference

17 June 2018

number of pages

7

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

17 June 2018

volume

93

1 reference

17 June 2018

issue

9

1 reference

17 June 2018

page(s)

1063-1069

1 reference

17 June 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Current therapy for chronic hepatitis C.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Hepatitis C virus envelope proteins bind lactoferrin

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

The treatment of chronic viral hepatitis

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin: molecular structure and biological function

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin, lactoferrin receptors and iron metabolism.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Inhibition with lactoferrin of in vitro infection with human herpes virus.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin: a general review.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

A second group of hepatitis C viruses

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Serum Myeloperoxidase and Lactoferrin in Neutropenia

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Plasma Myeloperoxidase and Lactoferrin Measured by Radioimmunoassay: Relations to Neutrophil Kinetics

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Peginterferon alfa-2a in patients with chronic hepatitis C.

18 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Significance of specific antibody assay for genotyping of hepatitis C virus

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5927129

Plasma lactoferrin levels in pregnancy and cystic fibrosis

15 August 2018

1 reference

12 December 2020

[Adverse drug reaction criteria of the Japan Society for Cancer Therapy]

1 reference

12 December 2020

Impairment of circulating lactoferrin in HIV-1 infection

1 reference

12 December 2020

Hepatitis C and hepatocellular carcinoma

1 reference

12 December 2020

10.1111/J.1349-7006.2002.TB02484.X

Identifiers

DOI

1 reference

17 June 2018

PMC publication ID

5927129

1 reference

17 June 2018

PubMed publication ID

12359061

1 reference

17 June 2018